olympia: adjuvant olaparib in gbrcam, her2-negative, high-risk, early breast cancer
Published 3 years ago • 1.2K plays • Length 2:44Download video MP4
Download video MP3
Similar videos
-
2:58
olympia: adjuvant olaparib following chemo significantly improves idfs
-
2:30
monarche: abemaciclib and adjuvant endocrine therapy for high-risk hr early breast cancer
-
1:26
monarche: investigating adjuvant abemacicilib for high-risk hr breast cancer
-
8:09
olaparib improves disease-free survival in high-risk early-stage her2-negative breast cancer wit...
-
2:10
monarche: adjuvant abemaciclib endocrine therapy in patients with hr , her2- high-risk ebc
-
7:42
the complexities of battling triple-negative breast cancer
-
2:24
astrazeneca olaparib gets cdsco panel nod for brca mutated her2 negative breast cancer
-
18:29
new frontiers in triple negative breast cancer
-
5:49
perspectives on the olympia study of adjuvant olaparib in early breast cancer | nadine tung
-
5:00
olympia: adjuvant olaparib delays recurrence of brca-mutant breast cancer | judy garber
-
3:50
olaparib beneficial for brca-mutated her2-negative breast cancer
-
5:31
fda d.i.s.c.o.: olaparib for gbrcam her2-negative metastatic breast cancer
-
2:23
natalee: ribociclib nsai as adjuvant treatment in patients with hr /her2− early breast cancer
-
6:28
quality of life results from olympia
-
1:00
olaparib or abemaciclib high-risk brca positive breast cancer?
-
1:36
olympia trial
-
3:30
final results from pallas: adjuvant palbociclib in hr /her2- early breast cancer
-
6:16
asco 2021 - highlights on shifting parpi to early breast cancer: the olympia study
-
1:10
olympia trial lynparza stops early breast cancer from coming back
-
1:45
the olympia clinical trial - results
-
4:18
adjuvant et /- 1 year of everolimus in patients with high-risk hr-positive, her2-negative bc
-
3:05
exploring the use of olaparib in advanced breast cancer